Genecast Got 300 Million Yuan Series D Financing
According to PEdaily.cn, Genecast (Beijing) Technology Co., Ltd. (Genecast) announced it has closed a Series D round financing of more than 300 million yuan, led by CICC Capital, with participation from Cowin Venture, Yahui Investment, and Matrix Partners China among other investors. Proceeds of this financing will mainly be used for the comprehensive upgrade of Genecast 's business.
Genecast was established in November 2014 and is located in Health Zhigu (Beijing) Mobile Health Industry Park. With the second-generation sequencing technology and bioinformatics as the core, the company is engaged in non-invasive and precise diagnosis and diagnosis of tumors, including lung cancer, intestinal cancer, liver cancer, breast cancer, etc. The company is committed to becoming a leader in improving the quality of life of cancer patients.
In March 2016, Genecast Technology's laboratory of 1200 square meters (Phase I) was completed. The laboratory is equipped with cutting-edge facilities. In June 2017, Genecast Laboratories (Phase II) is based on clinical molecular genetics testing and is engaged in molecular biology medical testing related to tumors, to provide tumor patients and doctors with the results of accurate medical examinations related to tumors, and assist doctors to establish precise treatment plans for individualized tumors.
About CICC Capital
CICC Capital is a wholly-owned subsidiary of China’s first joint venture investment bank, China International Capital Corporation Limited (CICC). As the private equity investment fund under CICC, CICC Capital provides private equity investment fund services, including making private investment development strategy, promoting business, allocating resources and managing the risk.
With a total AUM of nearly 300 billion yuan, CICC Capital has become one of the largest private equity funds in China.
About Cowin Venture (Cowin)
Founded in 2009, Cowin has built a business network covering China and the United States. Now Cowin has offices in Suzhou, Nanjing, Shanghai, Beijing, and Hong Kong.
The company has a sophisticated investment team with strong industry experiences and the ability to integrate resources, focusing on TMT and Healthcare, with a total AUM close to 5 billion yuan, consisting of seed funds, VC funds, and PE funds.